Table 2.
Fasting glucose SNPs associated with glucose response to atenolol or HCTZ monotherapy in PEAR Caucasian hypertensive patients (with p < 0.05).
| Gene | SNP | chromosome | Location (bp) |
Alleles¶ | Glucose- increasing allele |
MAF | N | BETA | SE | P |
|---|---|---|---|---|---|---|---|---|---|---|
| Atenolol | ||||||||||
| PROX1 | rs340874 | 1 | 212,225,879 | C/T | C | 0.48 | 232 | 2.39 | 0.73 | 0.0013* |
| ARAP1 | rs11603334 | 11 | 72,110,633 | A/G | A | 0.12 | 232 | 2.74 | 1.13 | 0.016 |
| Hydrochlorothiazide | ||||||||||
| SLC2A2 | rs11920090 | 3 | 172,200,215 | A/T | A | 0.14 | 224 | 3.09 | 1.34 | 0.022 |
Location: NCBI build 36 base pair position. MAF: minor allele frequency. Beta indicates the glucose response (in mg/dL) for each glucose increasing allele. SE: standard error. P values were linear regression p adjusted for baseline glucose, baseline insulin, age, gender, body mass index and principal components for ancestry.
¶
Alleles were presented as major/minor alleles.
*
p value that reached Bonferroni-corrected significance level.